O. Curet

2.5k total citations
40 papers, 1.9k citations indexed

About

O. Curet is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Neurology. According to data from OpenAlex, O. Curet has authored 40 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Cellular and Molecular Neuroscience, 24 papers in Molecular Biology and 9 papers in Neurology. Recurrent topics in O. Curet's work include Neuroscience and Neuropharmacology Research (16 papers), Neurotransmitter Receptor Influence on Behavior (15 papers) and Receptor Mechanisms and Signaling (11 papers). O. Curet is often cited by papers focused on Neuroscience and Neuropharmacology Research (16 papers), Neurotransmitter Receptor Influence on Behavior (15 papers) and Receptor Mechanisms and Signaling (11 papers). O. Curet collaborates with scholars based in France, Canada and United States. O. Curet's co-authors include B. Scatton, Claude de Montigny, Marc Savasta, A Dubois, Trevor Dennis, T Dennis, Christopher Carter, Pierre Blier, Pascal Barnéoud and H. Schoemaker and has published in prestigious journals such as Biological Psychiatry, Brain Research and Neuroscience.

In The Last Decade

O. Curet

39 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
O. Curet France 23 1.2k 692 347 279 259 40 1.9k
Christophe Melon France 24 1.3k 1.1× 543 0.8× 571 1.6× 234 0.8× 152 0.6× 46 1.8k
P. Worms France 22 942 0.8× 556 0.8× 253 0.7× 258 0.9× 153 0.6× 55 1.6k
Maria Rosaria Domenici Italy 29 1.4k 1.1× 712 1.0× 349 1.0× 301 1.1× 139 0.5× 78 2.3k
Cristina Cosi France 27 1.1k 0.9× 939 1.4× 168 0.5× 150 0.5× 200 0.8× 51 2.1k
Dominique Fage France 21 1.0k 0.9× 780 1.1× 184 0.5× 181 0.6× 232 0.9× 38 1.7k
Luisa Ugedo Spain 29 1.7k 1.4× 879 1.3× 550 1.6× 297 1.1× 160 0.6× 95 2.5k
H. Wachtel Germany 26 1.3k 1.1× 969 1.4× 624 1.8× 123 0.4× 174 0.7× 47 2.2k
Karen E. Asin United States 29 1.5k 1.2× 760 1.1× 249 0.7× 494 1.8× 208 0.8× 71 2.4k
Marc De Ryck Belgium 21 773 0.6× 452 0.7× 296 0.9× 284 1.0× 219 0.8× 39 1.7k
Luca Raiteri Italy 25 1.3k 1.1× 888 1.3× 248 0.7× 183 0.7× 125 0.5× 55 1.9k

Countries citing papers authored by O. Curet

Since Specialization
Citations

This map shows the geographic impact of O. Curet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O. Curet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O. Curet more than expected).

Fields of papers citing papers by O. Curet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by O. Curet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O. Curet. The network helps show where O. Curet may publish in the future.

Co-authorship network of co-authors of O. Curet

This figure shows the co-authorship network connecting the top 25 collaborators of O. Curet. A scholar is included among the top collaborators of O. Curet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with O. Curet. O. Curet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Biton, Bruno, Santhosh Sethuramanujam, Arin Bhattacharjee, et al.. (2011). The Antipsychotic Drug Loxapine Is an Opener of the Sodium-Activated Potassium Channel Slack (Slo2.2). Journal of Pharmacology and Experimental Therapeutics. 340(3). 706–715. 33 indexed citations
2.
Saba, Wadad, Héric Valette, Marie‐Anne Peyronneau, et al.. (2009). [11C]SL25.1188, a new reversible radioligand to study the monoamine oxidase type B with PET: Preclinical characterisation in nonhuman primate. Synapse. 64(1). 61–69. 47 indexed citations
3.
Bottlaender, Michel, Frédéric Dollé, Ilonka Guenther, et al.. (2003). Mapping the Cerebral Monoamine Oxidase Type A: Positron Emission Tomography Characterization of the Reversible Selective Inhibitor [11C]Befloxatone. Journal of Pharmacology and Experimental Therapeutics. 305(2). 467–473. 23 indexed citations
4.
Dollé, Frédéric, Héric Valette, Yann Bramoullé, et al.. (2003). Synthesis and in vivo imaging properties of [11C]befloxatone: A novel highly potent positron emission tomography ligand for mono-amine oxidase-A. Bioorganic & Medicinal Chemistry Letters. 13(10). 1771–1775. 35 indexed citations
5.
Cohen, Caroline, et al.. (1999). Reduction of Oral Ethanol Self-Administration in Rats by Monoamine Oxidase Inhibitors. Pharmacology Biochemistry and Behavior. 64(3). 535–539. 16 indexed citations
6.
Barnéoud, Pascal & O. Curet. (1999). Beneficial Effects of Lysine Acetylsalicylate, a Soluble Salt of Aspirin, on Motor Performance in a Transgenic Model of Amyotrophic Lateral Sclerosis. Experimental Neurology. 155(2). 243–251. 78 indexed citations
7.
Rosenzweig, P., Alain Patat, O. Curet, et al.. (1998). Clinical pharmacology of befloxatone: a brief review. Journal of Affective Disorders. 51(3). 305–312. 17 indexed citations
8.
Griebel, Guy, O. Curet, Ghislaine Perrault, & D. J. Sanger. (1998). Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine–oxidase activity and monoamine levels. Neuropharmacology. 37(7). 927–935. 47 indexed citations
9.
Curet, O., et al.. (1998). Aspirin and Salicylate Protect Against MPTP‐Induced Dopamine Depletion in Mice. Journal of Neurochemistry. 71(4). 1635–1642. 185 indexed citations
10.
Haddjeri, Nasser, Claude de Montigny, O. Curet, & Pierre Blier. (1998). Effect of the reversible monoamine oxidase-A inhibitor befloxatone on the rat 5-hydroxytryptamine neurotransmission. European Journal of Pharmacology. 343(2-3). 179–192. 32 indexed citations
11.
Luthringer, R., et al.. (1996). Pharmacoelectroencephalographic Profile of Befloxatone, a New Reversible MAO-A Inhibitor, in Healthy Subjects. Neuropsychobiology. 34(2). 98–105. 14 indexed citations
12.
Patat, Alain, F. Le Coz, C. Dubruc, et al.. (1996). Pharmacodynamics and Pharmacokinetics of Two Dose Regimens of Befloxatone, a New Reversible and Selective Monoamine Oxidase Inhibitor, at Steady State in Healthy Volunteers. The Journal of Clinical Pharmacology. 36(3). 216–229. 16 indexed citations
13.
Curet, O., et al.. (1996). Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile.. Journal of Pharmacology and Experimental Therapeutics. 277(1). 253–264. 18 indexed citations
14.
15.
Rovei, V., et al.. (1994). Biochemical pharmacology of befloxatone (MD370503), a new potent reversible MAO-A inhibitor. PubMed. 41. 339–347. 9 indexed citations
16.
Curet, O., Claude de Montigny, & Pierre Blier. (1992). Effect of desipramine and amphetamine on noradrenergic neurotransmission: electrophysiological studies in the rat brain. European Journal of Pharmacology. 221(1). 59–70. 31 indexed citations
17.
Blier, Pierre, O. Curet, Yves Chaput, & Claude de Montigny. (1991). Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine—II. Effects of acute administration of 1-PP and long-term adminstration of tandospirone on noradrenergic neurotransmission. Neuropharmacology. 30(7). 691–701. 32 indexed citations
18.
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christophe Melon Breakdown of academic impact, for papers by P. Worms Breakdown of academic impact, for papers by Maria Rosaria Domenici Breakdown of academic impact, for papers by Cristina Cosi Breakdown of academic impact, for papers by Dominique Fage Breakdown of academic impact, for papers by Luisa Ugedo Breakdown of academic impact, for papers by H. Wachtel Breakdown of academic impact, for papers by Karen E. Asin Breakdown of academic impact, for papers by Marc De Ryck Breakdown of academic impact, for papers by Luca Raiteri
Rankless by CCL
2026